OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic corneal pain.
The company has chosen to end its Phase 2 trial being conducted at the Tufts Medical Center in Boston early, with 17 patients having completed the study.
It expects the analysis of the data from these patients will take no longer than six weeks, to be followed by a meeting with the Food and Drug Administration (FDA).
“The decision to close the trial now significantly cuts the time to our requesting an end-of-phase 2 meeting with FDA to explore accelerated plans for the drug’s further clinical development,” OKYO Pharma CEO Dr Gary Jacob said.
“Urcosimod has already demonstrated favorable safety and placebo-like tolerability in our previous 240-patient Phase 2 trial.”
The company noted that several patients who have completed the trial have requested continued compassionate use of urcosimod, which OKYO is seeking to arrange with Tufts Medical Center with FDA consent.
Shares of OKYO gained 1% on Wednesday morning in New York.